Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 8 '25)

Image
By G.M.

 


    Antiviral Res

  1. PADEY B, Droillard C, Duliere V, Fouret J, et al
    Host-targeted repurposed diltiazem enhances the antiviral activity of direct acting antivirals against Influenza A virus and SARS-CoV-2.
    Antiviral Res. 2025 Mar 4:106138. doi: 10.1016/j.antiviral.2025.106138.
    PubMed         Abstract available

  2. INOUE A, Ichikawa T, Wada D, Maruyama S, et al
    M49L and other drug resistance mutations emerging in individuals after administration of ensitrelvir in Japanese clinical settings.
    Antiviral Res. 2025;236:106118.
    PubMed         Abstract available

  3. UEHARA T, Yotsuyanagi H, Ohmagari N, Doi Y, et al
    Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CL(pro) detected in the SCORPIO-SR phase 3 trial.
    Antiviral Res. 2025 Jan 30:106097. doi: 10.1016/j.antiviral.2025.106097.
    PubMed         Abstract available


    Biochem Biophys Res Commun

  4. IMBIAKHA B, Ezzatpour S, Buchholz DW, Poosala S, et al
    Novel nanobody drug conjugate as a prophylactic or therapeutic against SARS-CoV-2 infection in mice.
    Biochem Biophys Res Commun. 2025;753:151480.
    PubMed         Abstract available


    BMC Pediatr

  5. XU YY, Dai ZZ, Zhou H, Li H, et al
    Postoperative cardiopulmonary complications in children with preoperative Omicron SARS-CoV-2 variants infection: a single-center retrospective cohort study.
    BMC Pediatr. 2025;25:162.
    PubMed         Abstract available


    Epidemiol Infect

  6. WASIK BR, Damodaran L, Maltepes MA, Voorhees IEH, et al
    THE EVOLUTION AND EPIDEMIOLOGY OF H3N2 CANINE INFLUENZA VIRUS AFTER 20 YEARS IN DOGS.
    Epidemiol Infect. 2025 Mar 5:1-38. doi: 10.1017/S0950268825000251.
    PubMed        


    J Infect

  7. YANG J, Zheng S, Sun J, Wu H, et al
    A human-infecting H10N5 avian influenza virus: clinical features, virus reassortment, receptor-binding affinity, and possible transmission routes.
    J Infect. 2025 Mar 4:106456. doi: 10.1016/j.jinf.2025.106456.
    PubMed         Abstract available

  8. SONG Y, Gong YN, Chen KF, Smith DK, et al
    Global epidemiology, seasonality and climatic drivers of the four human parainfluenza virus types.
    J Infect. 2025 Feb 26:106451. doi: 10.1016/j.jinf.2025.106451.
    PubMed         Abstract available

  9. FENG Q, Wang J, Wang X, Tian J, et al
    Clinical epidemiological characteristics of hospitalized pediatric viral community-acquired pneumonia in China.
    J Infect. 2025;90:106450.
    PubMed         Abstract available

  10. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
    The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose.
    J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447.
    PubMed         Abstract available

  11. LIANG C, Begier E, Hagel S, Ankert J, et al
    Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the German prospective ThEpiCAP study.
    J Infect. 2025;90:106440.
    PubMed         Abstract available

  12. NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al
    Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
    J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436.
    PubMed         Abstract available

  13. QUINT JK, Dube S, Carty L, Yokota R, et al
    Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study.
    J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432.
    PubMed         Abstract available


    J Virol Methods

  14. GASTELBONDO-PASTRANA B, Florez L, Guzman C, Torres K, et al
    Phenol-free in-house kit for RNA extraction with applicability to SARS-CoV-2 genomic sequencing studies: A contribution to biotechnological sovereignty in Colombia.
    J Virol Methods. 2025;334:115116.
    PubMed         Abstract available


    Lancet

  15. THE LANCET
    H5N1 avian influenza: technical solutions, political challenges.
    Lancet. 2025;405:671.
    PubMed        


    N Engl J Med

  16. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed         Abstract available


    PLoS Comput Biol

  17. ZHAN X, Xu Q, Zheng Y, Lu G, et al
    Reliability-enhanced data cleaning in biomedical machine learning using inductive conformal prediction.
    PLoS Comput Biol. 2025;21:e1012803.
    PubMed         Abstract available

  18. CASABURI P, Dall'Amico L, Gozzi N, Kalimeri K, et al
    Resilience of mobility network to dynamic population response across COVID-19 interventions: Evidences from Chile.
    PLoS Comput Biol. 2025;21:e1012802.
    PubMed         Abstract available


    PLoS One

  19. KLEBER M, Meunier-Beillard N, Fournel I, Ksiazek E, et al
    Barriers to and facilitators of rehabilitation according to socio-economic status, after acute respiratory distress syndrome due to COVID-19: A qualitative study in the RECOVIDS cohort.
    PLoS One. 2025;20:e0316318.
    PubMed         Abstract available

  20. BURRY RD, Pike A, Maddigan J, Rauman P, et al
    New graduate nurses' experiences with and perceptions of their mental health and well-being during the COVID-19 pandemic: An interpretive description study protocol.
    PLoS One. 2025;20:e0315852.
    PubMed         Abstract available

  21. RICHARD L, Carter B, Liu M, Nisenbaum R, et al
    Incidence and factors associated with SARS-CoV-2 infection and re-infection among people experiencing homelessness in Toronto, Canada: A prospective cohort study.
    PLoS One. 2025;20:e0319296.
    PubMed         Abstract available

  22. MANNA RM, Rahman MH, Ara T, Usmani NG, et al
    Impact of COVID-19 on In-Patient and Out-Patient services in Bangladesh.
    PLoS One. 2025;20:e0315626.
    PubMed         Abstract available

  23. VESELI B, Seifert R, Clement M, Shehu E, et al
    Trading-off health safety, civil liberties, and unemployment based on communication strategies: the social dilemma in fighting pandemics.
    PLoS One. 2025;20:e0318541.
    PubMed         Abstract available

  24. KUMADOR DK, Opoku-Mensah A, Tackie-Ofosu V, Mahama S, et al
    Preterm delivery in Ghana: challenges and implications for maternal mental health trajectories.
    PLoS One. 2025;20:e0317147.
    PubMed         Abstract available

  25. PUTRI ND, Laksanawati IS, Husada D, Kaswandani N, et al
    A systematic review of post COVID-19 condition in children and adolescents: Gap in evidence from low-and -middle-income countries and the impact of SARS-COV-2 variants.
    PLoS One. 2025;20:e0315815.
    PubMed         Abstract available

  26. KATZ VS, Jordan AB, Ognyanova K
    Digital inequalities and U.S. undergraduate outcomes over the first two years of the COVID-19 pandemic.
    PLoS One. 2025;20:e0319000.
    PubMed         Abstract available

  27. DI RISO D, Spaggiari S, Calignano G, Rigo P, et al
    Wearing face masks when no longer mandatory: An exploratory study about attitudinal and psychological health factors in a large Italian sample.
    PLoS One. 2025;20:e0314607.
    PubMed         Abstract available

  28. KWAN AT, Vargo J, Kurtz C, Panditrao M, et al
    The integration of health equity into policy to reduce disparities: Lessons from California during the COVID-19 pandemic.
    PLoS One. 2025;20:e0316517.
    PubMed         Abstract available

  29. AL MASOODI WTM, Radhi SW, Abdalsada HK, Niu M, et al
    Increased galanin-galanin receptor 1 signaling, inflammation, and insulin resistance are associated with affective symptoms and chronic fatigue syndrome due to long COVID.
    PLoS One. 2025;20:e0316373.
    PubMed         Abstract available

  30. KENDZERSKA T, Pugliese M, Manuel D, Sadatsafavi M, et al
    Healthcare utilization trends in adults with asthma or COPD during the first year of COVID-19 pandemic in comparison to pre-pandemic: A population-based study.
    PLoS One. 2025;20:e0316553.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  31. MA Y, Wang J, Cui F, Tang L, et al
    Independent and combined effects of long-term air pollution exposure and genetic predisposition on COVID-19 severity: A population-based cohort study.
    Proc Natl Acad Sci U S A. 2025;122:e2421513122.
    PubMed         Abstract available

  32. ZHU Y, Cong Y, Sun Y, Sheng S, et al
    Molecular patterns of matrix protein 1 (M1): A strong predictor of adaptive evolution in H9N2 avian influenza viruses.
    Proc Natl Acad Sci U S A. 2025;122:e2423983122.
    PubMed         Abstract available


    Vaccine

  33. RAJA AI, Connor RI, Ashare A, Weiner JA, et al
    Binding and neutralising antibodies to respiratory syncytial virus and influenza A virus in serum and bronchoalveolar lavage fluid of healthy adults in the United States: A cross-sectional study.
    Vaccine. 2025;53:126936.
    PubMed         Abstract available

  34. COTTER LM, Hopkins-Sheets M, Yang S, Passmore SR, et al
    Increasing confidence for pediatric COVID-19 and influenza vaccines using messages affirming parental autonomy: A randomized online experiment.
    Vaccine. 2025;53:126947.
    PubMed         Abstract available

  35. NIU Y, Yan Y, Hu Y, Yang X, et al
    A novel tetravalent influenza vaccine based on one chimpanzee adenoviral vector.
    Vaccine. 2025;53:126959.
    PubMed         Abstract available

  36. RIGAMONTI V, Torri V, Morris SK, Ieva F, et al
    Real-world effectiveness of influenza vaccination in preventing influenza and influenza-like illness in children.
    Vaccine. 2025;53:126946.
    PubMed         Abstract available

  37. MACKENZIE LJ, Bousie JA, Newman P, Cunningham J, et al
    What three years of COVID-19 vaccine administration reveals about the incidence of shoulder injury related to vaccine administration (SIRVA).
    Vaccine. 2025;51:126892.
    PubMed         Abstract available

  38. ATTI A, England A, Sung J, Foulkes S, et al
    Estimating neutralising antibody responses against emerging SARS-CoV-2 variants utilising convalescent sera before the roll-out of XBB-lineage vaccines.
    Vaccine. 2025;51:126898.
    PubMed         Abstract available

  39. MEYERS E, De Rop L, Deschepper E, Duysburgh E, et al
    SARS-CoV-2 seroreversion and all-cause mortality in nursing home residents and staff post-primary course vaccination in Belgium between February and December 2021.
    Vaccine. 2025;51:126865.
    PubMed         Abstract available

  40. HALL C, Lanning J, Romano CJ, Bukowinski AT, et al
    COVID-19 vaccine initiation in pregnancy and risk for adverse neonatal outcomes among United States military service members, January-December 2021.
    Vaccine. 2025;51:126894.
    PubMed         Abstract available

  41. SMITH DS, Postma M, Fisman D, Mould-Quevedo J, et al
    Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs.
    Vaccine. 2025;51:126879.
    PubMed         Abstract available

  42. OLIVIERI G, Amodio D, Manno EC, Santilli V, et al
    Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies.
    Vaccine. 2025;51:126853.
    PubMed         Abstract available


    Virology

  43. LAI SK, Lee ZQ, Tan TI, Tan BH, et al
    Evidence that the cell glycocalyx envelops respiratory syncytial virus (RSV) particles that form on the surface of RSV-infected human airway cells.
    Virology. 2025;604:110415.
    PubMed         Abstract available

  44. HILLS FR, Geoghegan JL, Bostina M
    Architects of infection: A structural overview of SARS-related coronavirus spike glycoproteins.
    Virology. 2025;604:110383.
    PubMed         Abstract available

  45. YAMAMOTO A, Ito H, Sakaguchi T, Higashiura A, et al
    Structural insights into nucleocapsid protein variability: Implications for PJ34 efficacy against SARS-CoV-2.
    Virology. 2025;604:110411.
    PubMed         Abstract available

  46. FRAGOSO-SAAVEDRA M, Liu Q
    Towards developing multistrain PEDV vaccines: Integrating basic concepts and SARS-CoV-2 pan-sarbecovirus strategies.
    Virology. 2025;604:110412.
    PubMed         Abstract available

  47. SUGRUE RJ, Tan BH
    The link between respiratory syncytial virus (RSV) morphogenesis and virus transmission: Towards a paradigm for understanding RSV transmission in the upper airway.
    Virology. 2025;604:110413.
    PubMed         Abstract available

  48. SHI H, Inankur B, Yin J
    Serum starvation impacts rhinovirus spread from cell to cell.
    Virology. 2025;604:110408.
    PubMed         Abstract available

  49. PATEL H, Kukol A
    Harnessing viral internal proteins to combat flu and beyond.
    Virology. 2025;604:110414.
    PubMed         Abstract available

  50. SAHA A, Choudhary S, Walia P, Kumar P, et al
    Transformative approaches in SARS-CoV-2 management: Vaccines, therapeutics and future direction.
    Virology. 2025;604:110394.
    PubMed         Abstract available

  51. HE M, He CQ, Ding NZ
    Human viruses: An ever-increasing list.
    Virology. 2025;604:110445.
    PubMed         Abstract available

  52. PORTER SM, Hartwig AE, Quilici M, Bosco-Lauth AM, et al
    Intraspecific SARS-CoV-2 Delta variant transmission among red fox (Vulpes vulpes) and striped skunk (Mephitis mephitis).
    Virology. 2025;604:110446.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »